AegirBio announces first clinical saliva TDM study in US
PRESS RELEASE October 14, 2022 AegirBio is pleased to announce the initiation of a clinical study to evaluate saliva based measurements of natalizumab in multiple sclerosis patients. The goal of the study is to confirm that our novel saliva calibration method can be used to accurately measure therapeutic drug levels in saliva as compared to blood. The study is being performed in collaboration with Dr. John Foley at the Rocky Mountain MS Clinic in Salt Lake City.“To our knowledge, this is the first such study of its kind and will hopefully open the door to non-